Gemcitabine and oxaliplatin with a chemotherapy pump for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests gemcitabine plus oxaliplatin chemotherapy, and whether adding a chemotherapy pump (with floxuridine and dexamethasone) delivered to the liver improves outcomes. It is for people whose intrahepatic cholangiocarcinoma cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your cancer is intrahepatic cholangiocarcinoma confirmed by pathology (biopsy/tissue test).
- Your cancer has spread only within the liver (regional lymph nodes are allowed if they can be removed).
- Your disease is considered too difficult to remove with surgery, and you must be a candidate for anesthesia and a liver artery pump procedure.
- Your overall health is good enough for treatment (ECOG 0–1), and your blood counts and liver/kidney tests meet thresholds.
- You must not have had prior systemic chemotherapy for this bile duct cancer, prior floxuridine (FUDR) treatment, or certain liver radiation/ablation procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
This trial tests whether adding a liver-directed treatment (HAI floxuridine or SIRT) to standard chemotherapy (GemOx) is more effective for people with bile duct cancer inside the liver that cannot be removed by surgery. It may be an option for those whose cancer is only in the liver or nearby lymph nodes.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of low-dose chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (PD-1/PD-L1 antibody) for people with intrahepatic cholangiocarcinoma, a type of bile duct cancer inside the liver. The goal is to see if this combination can help shrink tumors or slow their growth.
This study tests a combination of two drugs (surufatinib and toripalimab) plus a chemo infusion directly into the liver (HAIC) for people with bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.